News and Announcements
Actinogen Medical CEO Interview
- Published September 23, 2016 11:18AM UTC
- Publisher Wholesale Investor
- Categories Executive Interviews
Actinogen Medical Ltd (ASX: ACW) is an Australian, publicly-listed early clinical-stage biotechnology company focused on the treatment of cognitive impairment and Alzheimer’s disease.
Actinogen is developing Xanamem™ as a novel treatment approach to Alzheimer’s disease and other age-related neurodegenerative diseases. Xanamem™ displays high potency and selectivity for inhibiting the activity of a key enzyme in the brain, which converts cortisone to cortisol. Cortisol is also known as the stress hormone, and elevated levels of cortisol has previously been linked to cognitive impairment. The pivotal human proof of concept study, also known as XanADu, commenced in 2Q2016.
Please listen to Dr. Bill Ketelbey, Founder and CEO & Managing Director of Actinogen Medical below.
Executive Interviews
Cosmo Innovations Founder Eyes Global Rollout of SkinGate, IPO by 2027
Dr. Mathew Jafarzadeh, founder of Cosmo Innovations, is set to revolutionize the $65 billion home beauty tech market with SkinGate, a patented skincare infusion device. Following his presentation at Emergence 2025, he revealed plans for a global rollout, aiming for a 2027 IPO on NASDAQ or the Hong Kong Exchange. Discover how SkinGate, backed by 110+ patents, seeks to attract “smart capital” and redefine skincare delivery.
Stop Leaving Millions on the Table: The Investor Secret You’re Missing!
In an Australian business landscape increasingly defined by volatility and intense competition for capital, the art of robust stakeholder relations has evolved beyond a mere governance checkbox. For founders, boards, and executive teams, the ability to genuinely inform and engage investors isn’t just about meeting disclosure requirements; it’s a strategic imperative that directly impacts capital […]
Ecosystems Over Exit: Callum Laing on Disrupting Small Business M&A
At Emergence Singapore, Callum Laing of Veblen Director Program presented a bold new vision for small business M&A: “Ecosystems Over Exit.” He shared how his Unity Group takes cash-generating businesses public, focusing on growth over immediate founder exit. Discover his unique approach, how interconnected ecosystems drive massive deal flow, and a three-step framework for any business to amplify reach and capital raising.
Backed By Leading Investment Groups and Family Offices
